Literature DB >> 18385383

Killin is a p53-regulated nuclear inhibitor of DNA synthesis.

Yong-Jig Cho1, Peng Liang.   

Abstract

Cell growth arrest and apoptosis are two best-known biological functions of tumor-suppressor p53. However, genetic evidence indicates that not only is p21 the major mediator of G(1) arrest, but also it can prevent apoptosis with an unknown mechanism. Here, we report the discovery of a p53 target gene dubbed killin, which lies in close proximity to pten on human chromosome 10 and encodes a 20-kDa nuclear protein. We show that Killin is not only necessary but also sufficient for p53-induced apoptosis. Genetic and biochemical analysis demonstrates that Killin is a high-affinity DNA-binding protein, which potently inhibits eukaryotic DNA synthesis in vitro and appears to trigger S phase arrest before apoptosis in vivo. The DNA-binding domain essential for DNA synthesis inhibition was mapped to within 42 amino acid residues near the N terminus of Killin. These results support Killin as a missing link between p53 activation and S phase checkpoint control designed to eliminate replicating precancerous cells, should they escape G(1) blockade mediated by p21.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385383      PMCID: PMC2291080          DOI: 10.1073/pnas.0705410105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells.

Authors:  Jian Yu; Zhenghe Wang; Kenneth W Kinzler; Bert Vogelstein; Lin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

2.  Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction.

Authors:  P Liang; A B Pardee
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

3.  Global analysis of gene expression by differential display: a mathematical model.

Authors:  Shitao Yang; Peng Liang
Journal:  Mol Biotechnol       Date:  2004-07       Impact factor: 2.695

4.  CYFIP2, a direct p53 target, is leptomycin-B sensitive.

Authors:  Roger S Jackson; Yong-Jig Cho; Susanne Stein; Peng Liang
Journal:  Cell Cycle       Date:  2007-01-29       Impact factor: 4.534

5.  Genetic determinants of p53-induced apoptosis and growth arrest.

Authors:  K Polyak; T Waldman; T C He; K W Kinzler; B Vogelstein
Journal:  Genes Dev       Date:  1996-08-01       Impact factor: 11.361

6.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

Authors:  X Chen; L J Ko; L Jayaraman; C Prives
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

7.  Simian virus 40 DNA replication in vitro.

Authors:  J J Li; T J Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  30 in total

1.  Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

Authors:  Kristi L Bennett; Jessica Mester; Charis Eng
Journal:  JAMA       Date:  2010-12-22       Impact factor: 56.272

2.  Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Authors:  Joanne Ngeow; Jessica Mester; Lisa A Rybicki; Ying Ni; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  KSRP modulates melanoma growth and efficacy of vemurafenib.

Authors:  Wenwen Liu; Chu-Fang Chou; Shanrun Liu; David Crossman; Nabiha Yusuf; Yunkun Wu; Ching-Yi Chen
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-06-30       Impact factor: 4.490

Review 4.  S-phase-coupled apoptosis in tumor suppression.

Authors:  Yong-Jig Cho; Peng Liang
Journal:  Cell Mol Life Sci       Date:  2011-03-25       Impact factor: 9.261

5.  Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?

Authors:  S Adeleh Razavi; Mohammad Hossein Modarressi; Parichehr Yaghmaei; S Mohammad Tavangar; Mehdi Hedayati
Journal:  Endocrine       Date:  2017-07-28       Impact factor: 3.633

6.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

7.  Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.

Authors:  Ke Hu; Meng Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-23       Impact factor: 2.416

8.  GOPred: GO molecular function prediction by combined classifiers.

Authors:  Omer Sinan Saraç; Volkan Atalay; Rengul Cetin-Atalay
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

9.  Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.

Authors:  Emily A Nizialek; Charissa Peterson; Jessica L Mester; Erinn Downes-Kelly; Charis Eng
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

10.  Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage.

Authors:  Valeriya Solozobova; Alexandra Rolletschek; Christine Blattner
Journal:  BMC Cell Biol       Date:  2009-06-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.